More than 214 million women living in developing countries do not want to become pregnant but do not use effective contraceptive methods. For some of them, access to contraception is limited; for others, available methods are not acceptable or affordable. The goal of the Contraceptive Technology Innovation (CTI) Initiative is to develop new and strategically important contraceptives, through a strong focus on global partnerships, that ensures wide access to quality, affordable and acceptable products for those most in need.
Funded by the Bill & Melinda Gates Foundation, the CTI Initiative focuses on new contraceptive products that:
- Provide mid- to long duration of action
- Fill current gaps in the contraceptive method mix
- Are potentially acceptable to a large number of target users
- Are suitable for low-resource settings
- Can be procured at a low cost
- Will likely result in high public health impact
The CTI Initiative seeks opportunities to leverage strategic partnerships with product development scientists, university and contract laboratories, pharmaceutical companies, nongovernmental organizations, clinical research sites, manufacturing groups and service delivery organizations.
Work under the CTI Initiative supports development of longer-acting injectable contraceptives, biodegradable contraceptive implants and a microneedle patch platform for delivering contraceptives. A comparative evaluation of new intrauterine devices (IUDs) is also underway. Research under the grant is informed by user acceptability research, including recently completed studies in Uganda and Burkina Faso. This work leverages contraceptive research being conducted under Envision FP, funded by the U.S. Agency for International Development.
- Developed as part of the CTI Initiative, the Contraceptive Technology Innovation (CTI) Exchange provides a web platform for increasing access to resources on contraceptive research, development, registration, and introduction through collaboration and knowledge sharing. Two key resources on the site are Calliope, the Contraceptive Pipeline Database, with information on contraceptive products at various development stages or marketed only in limited regions and CAPRI, the Contraceptive Active Pharmaceutical Ingredient Database, which lists biochemical properties for 27 active pharmaceutical ingredients found in contraceptives, along with data on their pharmacology, toxicology, impurities, metabolites and use in marketed products.
For more information about the CTI Initiative, please contact us.